1. Home
  2. QDEL vs CTMX Comparison

QDEL vs CTMX Comparison

Compare QDEL & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuidelOrtho Corporation

QDEL

QuidelOrtho Corporation

HOLD

Current Price

$11.37

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$3.77

Market Cap

977.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QDEL
CTMX
Founded
1979
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
977.1M
IPO Year
2022
2015

Fundamental Metrics

Financial Performance
Metric
QDEL
CTMX
Price
$11.37
$3.77
Analyst Decision
Hold
Strong Buy
Analyst Count
4
10
Target Price
$28.25
$12.10
AVG Volume (30 Days)
3.0M
3.1M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
45.35
N/A
EPS
N/A
N/A
Revenue
$2,730,200,000.00
$76,201,000.00
Revenue This Year
$3.51
N/A
Revenue Next Year
$3.86
$7.61
P/E Ratio
N/A
$22.58
Revenue Growth
N/A
N/A
52 Week Low
$9.92
$1.72
52 Week High
$35.58
$8.21

Technical Indicators

Market Signals
Indicator
QDEL
CTMX
Relative Strength Index (RSI) 42.11 34.05
Support Level $10.86 $3.76
Resistance Level $12.85 $3.91
Average True Range (ATR) 0.92 0.22
MACD 0.17 -0.03
Stochastic Oscillator 51.88 9.87

Price Performance

Historical Comparison
QDEL
CTMX

About QDEL QuidelOrtho Corporation

QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: